Advanced in Osteomyelitis

Dr. Paul P. Cook

Infectious Disease
East Carolina University
628 E 12th St, 
Washington, NC 
Accepting New Patients
Offers Telehealth
43 Years of Experience
Advanced in Osteomyelitis
East Carolina University
628 E 12th St, 
Washington, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Cook is an Infectious Disease provider in Washington, North Carolina. Dr. Cook has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Osteomyelitis. His top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Myelitis, and AIDS Dysmorphic Syndrome. Dr. Cook is currently accepting new patients.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Osteomyelitis.

Graduate Year
1982
Specialties
Infectious Disease
Licenses
Internal Medicine in NC
Hospital Affiliations
Ecu Health Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

EAST CAROLINA UNIVERSITY
628 E 12th St, Washington, NC 27889
Other Locations
EAST CAROLINA UNIVERSITY
2100 Stantonsburg Rd, Greenville, NC 27834
EAST CAROLINA UNIVERSITY
E 5th St, Greenville, NC 27858
EAST CAROLINA UNIVERSITY
600 Moye Blvd, Greenville, NC 27834
EAST CAROLINA UNIVERSITY
2390 Hemby Ln, Greenville, NC 27834

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Enrollment Status: Completed
Publish Date: November 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Enrollment Status: Terminated
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Enrollment Status: Completed
Publish Date: January 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

46 Total Publications

SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infection.
SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infection.
Journal: The Journal of general virology
Published: September 03, 2025
Similar Doctors
Distinguished in Osteomyelitis
Dr. Thomas R. Gallaher
Infectious Disease
Distinguished in Osteomyelitis
Dr. Thomas R. Gallaher
Infectious Disease

East Carolina University

2390 Hemby Ln, 
Greenville, NC 
 (21.1 miles away)
252-744-4500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Gallaher is an Infectious Disease provider in Greenville, North Carolina. Dr. Gallaher is rated as a Distinguished provider by MediFind in the treatment of Osteomyelitis. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Nontuberculous Mycobacterial Lung Disease. Dr. Gallaher is currently accepting new patients.

Experienced in Osteomyelitis
Dr. Vicki M. Morris
Infectious Disease
Experienced in Osteomyelitis
Dr. Vicki M. Morris
Infectious Disease
3500 Arendell St, 
Morehead City, NC 
 (59.1 miles away)
252-247-2013
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vicki Morris is an Infectious Disease provider in Morehead City, North Carolina. Dr. Morris is rated as an Experienced provider by MediFind in the treatment of Osteomyelitis. Her top areas of expertise are Nontuberculous Mycobacterial Lung Disease, Osteomyelitis, Osteomyelitis in Children, and Strep Throat. Dr. Morris is currently accepting new patients.

Experienced in Osteomyelitis
Dr. Rabindra Ghimire
Infectious Disease | Hospital Medicine
Experienced in Osteomyelitis
Dr. Rabindra Ghimire
Infectious Disease | Hospital Medicine

East Carolina University

2100 Stantonsburg Rd, 
Greenville, NC 
 (20.9 miles away)
252-209-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rabindra Ghimire is an Infectious Disease specialist and a Hospital Medicine provider in Greenville, North Carolina. Dr. Ghimire is rated as an Experienced provider by MediFind in the treatment of Osteomyelitis. His top areas of expertise are Actinomycosis, Pulmonary Actinomycosis, Cryptococcosis, and Osteomyelitis. Dr. Ghimire is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cook's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile